Cancer stem cells and evolving novel therapies: a paradigm shift

Naveen, Sangeetha Vasudevaraj; Kalaivani, Kumar

doi:10.21037/sci.2018.01.03

Cited by 11 publications

(8 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Malignancy remains one of the most difficult to treat and serious diseases globally, resulting from unscheduled and unregulated cell proliferation. Furthermore, the methods of cancer treatment in recent decades including surgery, radiotherapy and conventional chemotherapy have not greatly reduced the rate of mortality in patients [45] with significant side effects present. Currently there is a requirement for a paradigm shift in treatment options with novel approaches at the forefront of innovative needs.…”

Section: Anti-cancer Activitymentioning

confidence: 99%

“…Bacteriocins offer many advantages for therapeutic application including their small size, biocompatibility, biodegradable and mostly non-immunogenic nature [45]. Issues arise, however, relating to bacteriocin stability, solubility, large-scale production and purification in sufficient quantities for general medical use.…”

Section: Factors Affecting Medical Applicationmentioning

confidence: 99%

See 1 more Smart Citation

Bacteriocins, Potent Antimicrobial Peptides and the Fight against Multi Drug Resistant Species: Resistance Is Futile?

Slattery²,

2020

View full text Add to dashboard Cite

Despite highly specialized international interventions and policies in place today, the rapid emergence and dissemination of resistant bacterial species continue to occur globally, threatening the longevity of antibiotics in the medical sector. In particular, problematic nosocomial infections caused by multidrug resistant Gram-negative pathogens present as a major burden to both patients and healthcare systems, with annual mortality rates incrementally rising. Bacteriocins, peptidic toxins produced by bacteria, offer promising potential as substitutes or conjugates to current therapeutic compounds. These non-toxic peptides exhibit significant potency against certain bacteria (including multidrug-resistant species), while producer strains remain insusceptible to the bactericidal peptides. The selectivity and safety profile of bacteriocins have been highlighted as superior advantages over traditional antibiotics; however, many aspects regarding their efficacy are still unknown. Although active at low concentrations, bacteriocins typically have low in vivo stability, being susceptible to degradation by proteolytic enzymes. Another major drawback lies in the feasibility of large-scale production, with these key features collectively limiting their current clinical application. Though such limitations require extensive research, the concept of expanding bacteriocins from food preservation to human health opens many fascinating doors, including novel drug delivery systems and anticancer treatment applications.

show abstract

Section: Anti-cancer Activitymentioning

confidence: 99%

Section: Factors Affecting Medical Applicationmentioning

confidence: 99%

Bacteriocins, Potent Antimicrobial Peptides and the Fight against Multi Drug Resistant Species: Resistance Is Futile?

Slattery²,

2020

View full text Add to dashboard Cite

show abstract

“…To determine the minimal inhibitory concentrations of lactic acid bacteria and other antagonist microorganisms isolated from natural sources of Kaliningrad region (soil, water bodies, plant objects) and being bacteriocins, primary and secondary metabolites were isolated by centrifugation [18]. In the first stage, the liquid nutrient medium was centrifuged at a rotor speed of 10,000 rpm for 20 min, the supernatant was separated and then filtered through 22 µm filters (Millipore, USA) into sterile tubes.…”

Section: Methodsmentioning

confidence: 99%

Determination of minimum inhibitory concentrations of lactic acid bacteria and other antagonist microorganisms

et al. 2021

View full text Add to dashboard Cite

Minimum inhibitory concentrations of lactic acid bacteria and other antagonist microorganisms isolated from natural sources of Kaliningrad region (soil, water bodies, plant objects) were determined. It was shown that the minimum inhibitory concentration of Pediococcus pentosaceus metabolites against Escherichia coli is 1.5·107 CFU/ml; Pseudomonas chlororaphis metabolites have no inhibitory effect against the test strain of Escherichia coli under study. It was found that Pediococcus damnosus metabolites adversely affect the growth of Escherichia coli, but at a concentration of 1.5·107 CFU/ml after 6-24 hours of cultivation. For metabolites isolated by Lactobacillus casei, the characteristic minimum inhibitory concentration with respect to the studied Escherichia coli strain is 1.5-107 CFU/ml, and for metabolites isolated by Lactobacillus fermentum, the minimum inhibitory concentration with respect to the studied Escherichia coli strain is 1.5·105 CFU/ml. At a concentration of Bacteroides hypermegas (Megamonas hypermegale) metabolites equal to 1.5·106 CFU/ml, an optical density lower than that of the control is observed. The minimum concentration of Pseudomonas syringae metabolites inhibiting Escherichia coli culture growth is 1.5-107 CFU/ml. For the metabolites Acetobacter aceti and Psychrobacter urativorans, the concentration of 1.5·107 CFU/ml is the lowest to inhibit the growth of Escherichia coli.

show abstract

“…Despite the increasing successes in some areas, the traditional treatments for most cancers are facing to increasing limitations. In spite of the availability of various methods for cancer treatments nowadays, which includes chemotherapy, surgery and radiotherapy, the rate of mortality remains consistent with significant side effects [58]. Globally, malignancy resulting from abnormal cells divisions and uncontrolled cell proliferation is one of the most difficult disease areas to treat.…”

Section: Antibiotics and Bacteriocins Constitute Promising Synergistic Combinations For Medical Therapymentioning

confidence: 99%

Broadening and Enhancing Bacteriocins Activities by Association with Bioactive Substances

Zgheib

Drider

Belguesmia

2020

IJERPH

View full text Add to dashboard Cite

Bacteriocins are antimicrobial peptides some of which are endowed with antiviral, anticancer and antibiofilm properties. These properties could be improved through synergistic interactions of these bacteriocins with other bioactive molecules such as antibiotics, phages, nanoparticles and essential oils. A number of studies are steadily reporting the effects of these combinations as new and potential therapeutic strategies in the future, as they may offer many incentives over existing therapies. In particular, bacteriocins can benefit from combination with nanoparticles which can improve their stability and solubility, and protect them from enzymatic degradation, reduce their interactions with other molecules and improve their bioavailability. Furthermore, the combination of bacteriocins with other antimicrobials is foreseen as a way to reduce the development of antibiotic resistance due to the involvement of several modes of action. Another relevant advantage of these synergistic combinations is that it decreases the concentration of each antimicrobial component, thereby reducing their side effects such as their toxicity. In addition, combination can extend the utility of bacteriocins as antiviral or anticancer agents. Thus, in this review, we report and discuss the synergistic effects of bacteriocin combinations as medicines, and also for other diverse applications including, antiviral, antispoilage, anticancer and antibiofilms.

show abstract

Cancer stem cells and evolving novel therapies: a paradigm shift

Cited by 11 publications

References 49 publications

Bacteriocins, Potent Antimicrobial Peptides and the Fight against Multi Drug Resistant Species: Resistance Is Futile?

Bacteriocins, Potent Antimicrobial Peptides and the Fight against Multi Drug Resistant Species: Resistance Is Futile?

Determination of minimum inhibitory concentrations of lactic acid bacteria and other antagonist microorganisms

Broadening and Enhancing Bacteriocins Activities by Association with Bioactive Substances

Contact Info

Product

Resources

About